WO2005112639A3 - Traitement ou prevention d'infections virales respiratoires au moyen de composes immunomodulateurs - Google Patents

Traitement ou prevention d'infections virales respiratoires au moyen de composes immunomodulateurs Download PDF

Info

Publication number
WO2005112639A3
WO2005112639A3 PCT/US2005/016595 US2005016595W WO2005112639A3 WO 2005112639 A3 WO2005112639 A3 WO 2005112639A3 US 2005016595 W US2005016595 W US 2005016595W WO 2005112639 A3 WO2005112639 A3 WO 2005112639A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
viral infections
respiratory viral
immunomodulator compounds
Prior art date
Application number
PCT/US2005/016595
Other languages
English (en)
Other versions
WO2005112639A2 (fr
Inventor
Cynthia W Tuthill
Alfred R Rudolph
Alexander A Kolobov
Andrey S Simbirtsev
Aleksandr V Petrov
Original Assignee
Sciclone Pharmaceuticals Inc
Cynthia W Tuthill
Alfred R Rudolph
Alexander A Kolobov
Andrey S Simbirtsev
Aleksandr V Petrov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ551457A priority Critical patent/NZ551457A/en
Application filed by Sciclone Pharmaceuticals Inc, Cynthia W Tuthill, Alfred R Rudolph, Alexander A Kolobov, Andrey S Simbirtsev, Aleksandr V Petrov filed Critical Sciclone Pharmaceuticals Inc
Priority to EA200602073A priority patent/EA011954B1/ru
Priority to JP2007513351A priority patent/JP2007537280A/ja
Priority to BRPI0511107-2A priority patent/BRPI0511107A/pt
Priority to MXPA06013050A priority patent/MXPA06013050A/es
Priority to EP05749596A priority patent/EP1748783A4/fr
Priority to CA002566062A priority patent/CA2566062A1/fr
Priority to AU2005244826A priority patent/AU2005244826B2/en
Publication of WO2005112639A2 publication Critical patent/WO2005112639A2/fr
Priority to IL179046A priority patent/IL179046A0/en
Priority to US11/558,281 priority patent/US20070087974A1/en
Publication of WO2005112639A3 publication Critical patent/WO2005112639A3/fr
Priority to NO20065518A priority patent/NO20065518L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un composé immunomodulateur administré à un patient présentant une infection virale respiratoire ou présentant un risque de développer cette infection.
PCT/US2005/016595 2004-05-14 2005-05-12 Traitement ou prevention d'infections virales respiratoires au moyen de composes immunomodulateurs WO2005112639A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP05749596A EP1748783A4 (fr) 2004-05-14 2005-05-12 Traitement ou prevention d'infections virales respiratoires au moyen de composes immunomodulateurs
EA200602073A EA011954B1 (ru) 2004-05-14 2005-05-12 Лечение или предупреждение респираторных вирусных инфекций с помощью иммуномодуляторов
JP2007513351A JP2007537280A (ja) 2004-05-14 2005-05-12 免疫調節性化合物を用いる呼吸器のウイルス感染の治療又は予防
BRPI0511107-2A BRPI0511107A (pt) 2004-05-14 2005-05-12 tratamento ou prevenção de infecções virais respiratórias com compostos imunomoduladores
MXPA06013050A MXPA06013050A (es) 2004-05-14 2005-05-12 Composiciones a base de compuestos inmunoreguladores para el tratamiento o prevencion de infecciones virales respiratorias.
NZ551457A NZ551457A (en) 2004-05-14 2005-05-12 Treatment or prevention of respiratory viral infections with immunomodulator compounds
CA002566062A CA2566062A1 (fr) 2004-05-14 2005-05-12 Traitement ou prevention d'infections virales respiratoires au moyen de composes immunomodulateurs
AU2005244826A AU2005244826B2 (en) 2004-05-14 2005-05-12 Treatment or prevention of respiratory viral infections with immunomodulator compounds
IL179046A IL179046A0 (en) 2004-05-14 2006-11-05 Treatment or prevention of respiratory viral infections with immunomodulator compounds
US11/558,281 US20070087974A1 (en) 2004-05-14 2006-11-09 Treatment or prevention of respiratory viral infections with immunomodulator compounds
NO20065518A NO20065518L (no) 2004-05-14 2006-11-29 Behandling eller forebyggelse av respiratoriske virusinfeksjoner med immunmodulerende forbindelser.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57094104P 2004-05-14 2004-05-14
US60/570,941 2004-05-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/558,281 Continuation US20070087974A1 (en) 2004-05-14 2006-11-09 Treatment or prevention of respiratory viral infections with immunomodulator compounds

Publications (2)

Publication Number Publication Date
WO2005112639A2 WO2005112639A2 (fr) 2005-12-01
WO2005112639A3 true WO2005112639A3 (fr) 2006-11-09

Family

ID=35428773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/016595 WO2005112639A2 (fr) 2004-05-14 2005-05-12 Traitement ou prevention d'infections virales respiratoires au moyen de composes immunomodulateurs

Country Status (17)

Country Link
US (1) US20070087974A1 (fr)
EP (1) EP1748783A4 (fr)
JP (1) JP2007537280A (fr)
KR (1) KR20070012522A (fr)
CN (1) CN1964731A (fr)
AU (1) AU2005244826B2 (fr)
BR (1) BRPI0511107A (fr)
CA (1) CA2566062A1 (fr)
EA (1) EA011954B1 (fr)
IL (1) IL179046A0 (fr)
MX (1) MXPA06013050A (fr)
NO (1) NO20065518L (fr)
NZ (1) NZ551457A (fr)
SG (1) SG169362A1 (fr)
UA (1) UA92586C2 (fr)
WO (1) WO2005112639A2 (fr)
ZA (1) ZA200610454B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2585457A1 (fr) 2004-10-27 2006-05-04 Sciclone Pharmaceuticals, Inc. Traitement ou prevention d'infections virales hemorragiques au moyen de composes immunomodulateurs
US20090074815A1 (en) * 2005-04-22 2009-03-19 Sciclone Pharmaceuticals, Inc. Immunomodulator Compounds as Vaccine Enhancers
KR20090119897A (ko) * 2007-02-13 2009-11-20 사이클론 파아머슈티컬 인코오퍼레이티드 점막의 질환으로 인한 조직 악화, 상처 또는 손상을 치료 또는 예방하는 방법
RU2007118237A (ru) * 2007-05-17 2008-11-27 ООО "Научно-производственна фирма Верта" (RU) Способ лечения аллергических заболеваний
RU2438694C1 (ru) * 2010-12-23 2012-01-10 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения вирусных заболеваний

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
WO2003013572A1 (fr) * 2001-06-08 2003-02-20 Sciclone Pharmaceuticals, Inc. Traitement de la tuberculose au moyen de composes immunomodulateurs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
WO2003013572A1 (fr) * 2001-06-08 2003-02-20 Sciclone Pharmaceuticals, Inc. Traitement de la tuberculose au moyen de composes immunomodulateurs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEN H.I. ET AL.: "Acute Respiratory Distress Dyndrome", J.BIOMED. SCI., vol. 10, no. 6, October 2003 (2003-10-01), pages 588 - 592, XP003001671 *

Also Published As

Publication number Publication date
WO2005112639A2 (fr) 2005-12-01
CN1964731A (zh) 2007-05-16
UA92586C2 (ru) 2010-11-25
EP1748783A2 (fr) 2007-02-07
EA011954B1 (ru) 2009-06-30
AU2005244826B2 (en) 2010-07-29
BRPI0511107A (pt) 2007-11-27
EA200602073A1 (ru) 2007-06-29
AU2005244826A1 (en) 2005-12-01
CA2566062A1 (fr) 2005-12-01
KR20070012522A (ko) 2007-01-25
MXPA06013050A (es) 2007-03-28
NZ551457A (en) 2009-12-24
US20070087974A1 (en) 2007-04-19
IL179046A0 (en) 2007-03-08
SG169362A1 (en) 2011-03-30
ZA200610454B (en) 2009-07-29
EP1748783A4 (fr) 2009-08-05
JP2007537280A (ja) 2007-12-20
NO20065518L (no) 2006-11-29

Similar Documents

Publication Publication Date Title
WO2006027628A3 (fr) Derives de naphtalimide en tant qu'agents antiviraux
WO2005084192A3 (fr) Nouveaux derives nucleosidiques de 2'-c-methyle
EA200900156A1 (ru) Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
EP1594512A4 (fr) Composes destines au traitement d'une infection virale
WO2008097599A3 (fr) Doublure antimicrobienne pour brassard de prise de pression artérielle
AU2003291885A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
WO2006033709A3 (fr) Nouveaux derives de nucleosides
WO2006050489A3 (fr) Methodes d'encapsulation, d'inactivation, et d'elimination d'infections virales par administration de compositions aux voies respiratoires
MX2009006764A (es) Pirimidinonas biciclicas y usos de la misma.
WO2005084315A3 (fr) Derives de pyranoindole et utilisation de ceux-ci pour le traitement d'une maladie ou d'une infection provoquee par le virus de l'hepatite c
WO2005112639A3 (fr) Traitement ou prevention d'infections virales respiratoires au moyen de composes immunomodulateurs
WO2006047702A3 (fr) Traitement ou prevention d'infections virales hemorragiques au moyen de composes immunomodulateurs
AU2003210659A1 (en) Combination therapy for treatment of hiv infection
WO2010138419A3 (fr) Matières et procédés de traitement d'infections virales
WO2009023356A3 (fr) Matériaux et procédés pour traiter les infections par le virus de la grippe
WO2004094991A3 (fr) Traitement ou prevention d'infections virales respiratoires au moyen de peptides de thymosine alpha
WO2006076169A3 (fr) Utilisation de composes immunomodulateurs pour le traitement ou la prevention d'infections virales genitales
ZA200800999B (en) Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
WO2010019698A3 (fr) Inhibition d'un calicivirus (norovirus)
WO2005065063A3 (fr) Utilisation du champignon <i>agaricus blazei murill </i>pour la production de medicaments appropries au traitement d'infections et d'allergies
AU2003295398A1 (en) Safer attenuated virus vaccines with missing or diminished latency of infection
WO2011046901A3 (fr) Antiviral à large spectre et procédés d'utilisation
WO2004056374A8 (fr) Utilisation de glycyrrhizine dans le traitement de patients atteints d'hepatite c resistant a une therapie standard
AU2002325602B2 (en) Use of a class of antiviral compounds for production of an agent for the treatment or prevention of a viral infection in the respiratory tract

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 179046

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2566062

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11558281

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/013050

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12006502258

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2007513351

Country of ref document: JP

Ref document number: 200580015527.0

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005244826

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005749596

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 551457

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020067025134

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 3667/KOLNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005244826

Country of ref document: AU

Date of ref document: 20050512

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005244826

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200610454

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1200602039

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200602073

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020067025134

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005749596

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11558281

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0511107

Country of ref document: BR